Oct. 25, 2018
Amgen announced on Wednesday, Oct. 24 it is making evolocumab available at a reduced list price in an effort to improve affordability and access for patients.
The announcement represents positive news for patients at risk for cardiovascular events.
Key outcomes from Amgen’s FOURIER trial, revealed in March 2017, revealed evolocumab significantly reduced the risk of cardiovascular events and were supported by long-term safety data.
Watch this special webinar hosted by the American Heart Association (AHA) and the Pacific Lipid Association (PLA) on how to equip healthcare providers and patients with proven tools to achieve better cholesterol management.
W. Virgil Brown, MD, FNLA and Ernst J. Schaefer, MD, FNLA, chairs of the Donald S. Fredrickson Conferences and Webinars on Familial Lipoprotein Disorders, are accepting case submissions for an upcoming webinar.
The deadline for submissions is Sunday, September 30. If a case is selected, the case submitter will be paired with one or several experts who will help them present and dissect your case in front of a live audience. The webinars will take place quarterly, and submissions may be considered for future webinars.
.jpg)
.png)
